- Home
- NBH vs CRMD Comparison
NBH vs CRMD Comparison
Compare NBH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- CRMD
- Stock Information
- Founded
- NBH 2002
- CRMD 2006
- Country
- NBH United States
- CRMD United States
- Employees
- NBH N/A
- CRMD N/A
- Industry
- NBH Finance/Investors Services
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- NBH Finance
- CRMD Health Care
- Exchange
- NBH Nasdaq
- CRMD Nasdaq
- Market Cap
- NBH 328.2M
- CRMD 279.7M
- IPO Year
- NBH N/A
- CRMD 2010
- Fundamental
- Price
- NBH $11.03
- CRMD $12.04
- Analyst Decision
- NBH
- CRMD Strong Buy
- Analyst Count
- NBH 0
- CRMD 5
- Target Price
- NBH N/A
- CRMD $13.60
- AVG Volume (30 Days)
- NBH 85.9K
- CRMD 909.2K
- Earning Date
- NBH 01-01-0001
- CRMD 11-12-2024
- Dividend Yield
- NBH 4.34%
- CRMD N/A
- EPS Growth
- NBH N/A
- CRMD N/A
- EPS
- NBH 0.12
- CRMD N/A
- Revenue
- NBH N/A
- CRMD $806,119.00
- Revenue This Year
- NBH N/A
- CRMD N/A
- Revenue Next Year
- NBH N/A
- CRMD $206.77
- P/E Ratio
- NBH $87.04
- CRMD N/A
- Revenue Growth
- NBH N/A
- CRMD 2107.40
- 52 Week Low
- NBH $8.75
- CRMD $2.57
- 52 Week High
- NBH $11.01
- CRMD $12.07
- Technical
- Relative Strength Index (RSI)
- NBH 45.73
- CRMD 90.23
- Support Level
- NBH $11.06
- CRMD $9.67
- Resistance Level
- NBH $11.17
- CRMD $10.66
- Average True Range (ATR)
- NBH 0.08
- CRMD 0.51
- MACD
- NBH -0.01
- CRMD 0.14
- Stochastic Oscillator
- NBH 33.86
- CRMD 98.48
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Intermediate Muni Fund is a closed-end management investment company that invests mainly in municipal securities. It aims to provide common stockholders a high level of current income exempt from Federal income tax.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.